Cargando…
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer
Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PL...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/ https://www.ncbi.nlm.nih.gov/pubmed/36386191 http://dx.doi.org/10.3389/fphar.2022.1019826 |
_version_ | 1784826612468940800 |
---|---|
author | You, Maojin Chen, Ruijia Wu, Qingfeng Zhu, Wei He, Ying Huang, Yufan |
author_facet | You, Maojin Chen, Ruijia Wu, Qingfeng Zhu, Wei He, Ying Huang, Yufan |
author_sort | You, Maojin |
collection | PubMed |
description | Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PLCHM, etoposide-carboplatin). However, owing to the higher cost of adebrelimab, it is unclear whether ADCHM is cost-effective compared with PLCHM. This study aimed to evaluate the cost-effectiveness of ADCHM as a first-line treatment for patients with ES-SCLC from the perspective of the Chinese healthcare system. Methods: A Markov model with three health states was developed to assess the cost-effectiveness of ADCHM as a first-line treatment option with ES-SCLC. Clinical data were obtained from the CAPSTONE-1 trial. Costs of the drug were calculated at national tender prices, and other costs and utility values were obtained from published literature. The outcomes included life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were used to validate the robustness of the model. Results: The ADCHM group achieved 1.21 QALYs (2.47 LYs) for $25,312, whereas the PLCHM group achieved 0.81 QALYs (1.59 LYs) for $14,846. The ICER for ADCHM versus PLCHM was $25914 per QALY gained. The variables with the greatest impact on the model results were the utility value of progressive disease, the utility value of progression-free survival, and the price of adebrelimab (100 mg). At a willingness-to-pay threshold of $37,653/QALY, ADCHM had an 89.1% probability of being cost-effective compared with PLCHM. Conclusion: ADCHM may be a cost-effective first-line treatment strategy for ES-SCLC from the perspective of the Chinese healthcare system. |
format | Online Article Text |
id | pubmed-9643856 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96438562022-11-15 Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer You, Maojin Chen, Ruijia Wu, Qingfeng Zhu, Wei He, Ying Huang, Yufan Front Pharmacol Pharmacology Background: The findings of the CAPSTONE-1 trial showed that adebrelimab in combination with chemotherapy (etoposide-carboplatin) (ADCHM) is clinically beneficial as a first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC), compared with placebo plus chemotherapy (PLCHM, etoposide-carboplatin). However, owing to the higher cost of adebrelimab, it is unclear whether ADCHM is cost-effective compared with PLCHM. This study aimed to evaluate the cost-effectiveness of ADCHM as a first-line treatment for patients with ES-SCLC from the perspective of the Chinese healthcare system. Methods: A Markov model with three health states was developed to assess the cost-effectiveness of ADCHM as a first-line treatment option with ES-SCLC. Clinical data were obtained from the CAPSTONE-1 trial. Costs of the drug were calculated at national tender prices, and other costs and utility values were obtained from published literature. The outcomes included life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios (ICERs). One-way sensitivity analysis and probabilistic sensitivity analysis were used to validate the robustness of the model. Results: The ADCHM group achieved 1.21 QALYs (2.47 LYs) for $25,312, whereas the PLCHM group achieved 0.81 QALYs (1.59 LYs) for $14,846. The ICER for ADCHM versus PLCHM was $25914 per QALY gained. The variables with the greatest impact on the model results were the utility value of progressive disease, the utility value of progression-free survival, and the price of adebrelimab (100 mg). At a willingness-to-pay threshold of $37,653/QALY, ADCHM had an 89.1% probability of being cost-effective compared with PLCHM. Conclusion: ADCHM may be a cost-effective first-line treatment strategy for ES-SCLC from the perspective of the Chinese healthcare system. Frontiers Media S.A. 2022-10-26 /pmc/articles/PMC9643856/ /pubmed/36386191 http://dx.doi.org/10.3389/fphar.2022.1019826 Text en Copyright © 2022 You, Chen, Wu, Zhu, He and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology You, Maojin Chen, Ruijia Wu, Qingfeng Zhu, Wei He, Ying Huang, Yufan Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title | Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title_full | Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title_fullStr | Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title_full_unstemmed | Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title_short | Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
title_sort | cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643856/ https://www.ncbi.nlm.nih.gov/pubmed/36386191 http://dx.doi.org/10.3389/fphar.2022.1019826 |
work_keys_str_mv | AT youmaojin costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer AT chenruijia costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer AT wuqingfeng costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer AT zhuwei costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer AT heying costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer AT huangyufan costeffectivenessanalysisofadebrelimabcombinedwithchemotherapyforextensivestagesmallcelllungcancer |